Cargando…

Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia

BACKGROUND: Reports of local and systemic side-effects of COVID-19 vaccination may play an important role in public confidence in the acceptance of the COVID-19 vaccine booster dose. METHODS: We conducted a retrospective cross-sectional study among adults living in Eastern Province of Saudi Arabia....

Descripción completa

Detalles Bibliográficos
Autores principales: Al-Matouq, Jenan Ahmed, Ali, Mohammad Daud, Al-Somali, Samiah Mohammad, Ahmad, Ayaz, Banu, Nuzhat, Patel, Munfis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568279/
https://www.ncbi.nlm.nih.gov/pubmed/36276167
http://dx.doi.org/10.1016/j.infpip.2022.100251
_version_ 1784809608982822912
author Al-Matouq, Jenan Ahmed
Ali, Mohammad Daud
Al-Somali, Samiah Mohammad
Ahmad, Ayaz
Banu, Nuzhat
Patel, Munfis
author_facet Al-Matouq, Jenan Ahmed
Ali, Mohammad Daud
Al-Somali, Samiah Mohammad
Ahmad, Ayaz
Banu, Nuzhat
Patel, Munfis
author_sort Al-Matouq, Jenan Ahmed
collection PubMed
description BACKGROUND: Reports of local and systemic side-effects of COVID-19 vaccination may play an important role in public confidence in the acceptance of the COVID-19 vaccine booster dose. METHODS: We conducted a retrospective cross-sectional study among adults living in Eastern Province of Saudi Arabia. A link to the survey was distributed to community members via WhatsApp, SMS, or e-mail. Participants' general and demographic information was also collected, as well as information about any local and systemic side-effects reported following vaccination. RESULTS: A total of 370/390 (94.87%) of respondents reported one or more side-effects. Pain or redness at the site of injection (88.92%), fatigue (43.78%), body pain fever (37.84%), and headache (15.95%) were the most commonly reported side-effects. Moreover, 2.43% of the participants reported side-effects needed to see a physician; only four were admitted to the hospital. The non-healthcare respondents (n=273 (97.15%), OR (95% CI) = 5.22 (2.02, 13.48, P <0.001) were more likely to report side-effects compared to the healthcare related respondents (n=36 (85.71%), OR (95% CI) = 0.25 (0.10, 0.70), P=0.013). CONCLUSION: According to this study, the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine was safe when given to Saudi Arabian adults. All reported side-effects were mild to moderate. The findings will likely persuade vaccine-hesitant individuals and pessimists to accept booster dose of COVID-19 vaccine.
format Online
Article
Text
id pubmed-9568279
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-95682792022-10-16 Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia Al-Matouq, Jenan Ahmed Ali, Mohammad Daud Al-Somali, Samiah Mohammad Ahmad, Ayaz Banu, Nuzhat Patel, Munfis Infect Prev Pract Original Research Article BACKGROUND: Reports of local and systemic side-effects of COVID-19 vaccination may play an important role in public confidence in the acceptance of the COVID-19 vaccine booster dose. METHODS: We conducted a retrospective cross-sectional study among adults living in Eastern Province of Saudi Arabia. A link to the survey was distributed to community members via WhatsApp, SMS, or e-mail. Participants' general and demographic information was also collected, as well as information about any local and systemic side-effects reported following vaccination. RESULTS: A total of 370/390 (94.87%) of respondents reported one or more side-effects. Pain or redness at the site of injection (88.92%), fatigue (43.78%), body pain fever (37.84%), and headache (15.95%) were the most commonly reported side-effects. Moreover, 2.43% of the participants reported side-effects needed to see a physician; only four were admitted to the hospital. The non-healthcare respondents (n=273 (97.15%), OR (95% CI) = 5.22 (2.02, 13.48, P <0.001) were more likely to report side-effects compared to the healthcare related respondents (n=36 (85.71%), OR (95% CI) = 0.25 (0.10, 0.70), P=0.013). CONCLUSION: According to this study, the Pfizer-BioNTech (BNT162b2) COVID-19 vaccine was safe when given to Saudi Arabian adults. All reported side-effects were mild to moderate. The findings will likely persuade vaccine-hesitant individuals and pessimists to accept booster dose of COVID-19 vaccine. Elsevier 2022-10-15 /pmc/articles/PMC9568279/ /pubmed/36276167 http://dx.doi.org/10.1016/j.infpip.2022.100251 Text en © 2022 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research Article
Al-Matouq, Jenan Ahmed
Ali, Mohammad Daud
Al-Somali, Samiah Mohammad
Ahmad, Ayaz
Banu, Nuzhat
Patel, Munfis
Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
title Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
title_full Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
title_fullStr Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
title_full_unstemmed Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
title_short Prevalence of side-effects associated with the booster dose of Pfizer-BioNTech (BNT162b2) of COVID-19 Vaccine among vaccinated adults in the Eastern province of Saudi Arabia
title_sort prevalence of side-effects associated with the booster dose of pfizer-biontech (bnt162b2) of covid-19 vaccine among vaccinated adults in the eastern province of saudi arabia
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568279/
https://www.ncbi.nlm.nih.gov/pubmed/36276167
http://dx.doi.org/10.1016/j.infpip.2022.100251
work_keys_str_mv AT almatouqjenanahmed prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia
AT alimohammaddaud prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia
AT alsomalisamiahmohammad prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia
AT ahmadayaz prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia
AT banunuzhat prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia
AT patelmunfis prevalenceofsideeffectsassociatedwiththeboosterdoseofpfizerbiontechbnt162b2ofcovid19vaccineamongvaccinatedadultsintheeasternprovinceofsaudiarabia